8037 — China Biotech Services Holdings Share Price
0.000.00%
Last trade - 00:00- HK$356.14m
- HK$502.51m
- HK$70.51m
- 17
- 13
- 66
- 20
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.34 | ||
| Price to Tang. Book | 2.82 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 5.05 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -62.76% | ||
| Return on Equity | -54.46% | ||
| Operating Margin | -300.27% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | HK$m | 655.79 | 623.76 | 1,851.53 | 211.99 | 70.51 | n/a | n/a | 3.55% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | -24.96 | +1112.18 | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
China Biotech Services Holdings Ltd, formerly Rui Kang Pharmaceutical Group Investments Ltd, is an investment holding company principally engaged in the provision of medical health check services. The Company operates its business through six segments. The Medical and Health Related Services segment provides medical laboratory testing services and health check services. The Insurance Brokerage segment is engaged in the provision of brokerage services. The Immunotherapy segment provides tumor immune call therapy, immune cell storage and health management services. The Pharmaceutical Products segment is engaged in the manufacture, research and development, sale and distribution of health related and pharmaceutical products. The Securities segment is engaged in the trading of securities. The Others segment is engaged in the money lending business and provision of logistic services.
Directors
- Xiaolin Liu CHM
- Song Huang CTO (37)
- Zheng Wang CCO (38)
- Xun He EDR (57)
- Miu Shun Wong SEC
- Chun Kit Ho NID (42)
- Hongji Qian NID (42)
- Guoxiang Yan NID (55)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- August 28th, 2013
- Public Since
- June 17th, 2004
- No. of Employees
- 141
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 975,731,150
- Address
- Room 1213, Tower A, New Mandarin Plaza
- Web
- http://www.cbshhk.com/
- Phone
- +852 null31883333
- Auditors
- RSM Hong Kong
Upcoming Events for 8037
Similar to 8037
Adicon Holdings
Stock Exchange of Hong Kong Limited
Aidigong Maternal & Child Health
Stock Exchange of Hong Kong Limited
Arrail
Stock Exchange of Hong Kong Limited
Suzhou Basecare Medical
Stock Exchange of Hong Kong Limited
Beijing Health (Holdings)
Stock Exchange of Hong Kong Limited
FAQ
What is the China Biotech Services Holdings share price?
As of Today at 19:52 UTC, shares in China Biotech Services Holdings are trading at HK$0.37. This share price information is delayed by 15 minutes.
How has the China Biotech Services Holdings share price performed this year?
Shares in China Biotech Services Holdings last closed at HK$0.37 and the price had moved by +30.36% over the past 365 days. In terms of relative price strength the China Biotech Services Holdings share price has outperformed the FTSE Developed Asia Pacific Index by +31.85% over the past year.
What are the analyst and broker recommendations for China Biotech Services Holdings?
There is no consensus recommendation for this security.
Find out moreWhat is the China Biotech Services Holdings dividend yield?
China Biotech Services Holdings does not currently pay a dividend.
Does China Biotech Services Holdings pay a dividend?
China Biotech Services Holdings does not currently pay a dividend.
When does China Biotech Services Holdings next pay dividends?
China Biotech Services Holdings does not currently pay a dividend.
How do I buy China Biotech Services Holdings shares?
To buy shares in China Biotech Services Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of China Biotech Services Holdings?
As of the previous close price of HK$0.37, shares in China Biotech Services Holdings had a market capitalisation of HK$356.14m.
Where are China Biotech Services Holdings shares listed?
Here are the trading details for China Biotech Services Holdings:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 8037
What kind of share is China Biotech Services Holdings?
Based on an overall assessment of its quality, value and momentum China Biotech Services Holdings is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a China Biotech Services Holdings share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the China Biotech Services Holdings share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like China Biotech Services Holdings. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +28.92%.
As of the last closing price of HK$0.37, shares in China Biotech Services Holdings were trading -7.08% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the China Biotech Services Holdings PE Ratio?
The China Biotech Services Holdings PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at HK$0.37.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of China Biotech Services Holdings?
China Biotech Services Holdings' management team is headed by:
- Xiaolin Liu - CHM
- Song Huang - CTO
- Zheng Wang - CCO
- Xun He - EDR
- Miu Shun Wong - SEC
- Chun Kit Ho - NID
- Hongji Qian - NID
- Guoxiang Yan - NID